Structure of synthetic catecholamines

This chapter is relevant to Section M2(ii) of the 2023 CICM Primary Syllabus, which expects the exam candidates to "describe the structure activity relationships of adrenergic and cholinergic drugs". The structure of the catecholamine molecule is briefly explored in a separate section. In short:

No discussion of the structure and activity relationship of phenyethylamines can be carried out without mention of PIHKAL, but the reader intending to maintain a stable relationship with the police is gently redirected to sources such as Barile (2019) or Runciman (1980)

Phenylephrine

Phenylephrine is a potent alpha agonist.   However it is not as potent as adrenaline, because it is missing a hydroxyl group from its aromatic ring. The  methyl substitution hanging off the terminal nitrogen group might suggest that this drug should have some kind of beta effects, but in actual fact it seems that the absence of one or both hydroxyl groups from the benzene ring confers a greatly reduced beta selectivity to this drug. For the same reason, phenylephrine is not a substrate for COMT. Its half-life is thus longer, because only MAO can digest it.

Isoprenaline

Isoprenaline is a potent nonselective beta agonist.   

This molecule is essentially the same as adrenaline, with the exception of the isopropyl amine substituent. This confers beta-selectivity, but does not aim the molecule specifically at beta-1 or beta-2 receptors.  With this abnormal-looking ethylamine tail, MAO wont touch it, but with COMT alone the halflife is still very brief, only a few minutes.

Salbutamol

Salbutamol is a potent beta-2 agonist.   Like isoprenaline, it has a large amine substituent to confer beta-selectivity; it also has a butyl substituent (actually, a ter-butyl) on the amine group which selects for beta-2 receptors. 

The ethylamine tail is even bigger, so neither MAO nor COMT want to metabolise it, and its halflife is about 90 minutes.

 Dobutamine

Dobutamine is a potent and moderately-selective beta-1 agonist. Its significant beta selectivity is assured by its huge,  monstrously elongated amine substituent group. It is usually present as a racemic mixture; the (+) isomer is a more potent beta-agonist. There is a beta-2 effect as well as a beta-1 effect. MAO cant handle such a weird-looking ethylamine group, but with  such a normal-looking catechol ring COMT makes short work of dobutamine, and its half-life is 2 minutes.

Dobutamine is weird, as it is a partial alpha-agonist, with a higher affinity (25 times greater!)  for the alpha-1 receptors than noradrenaline. That’s the racemic mixture, anyway. (-) and (+) dobutamine both have the same affinity for the alpha-1 receptor, but (+)dobutamine has practically no alpha-agonist activity  (which essentially makes it an antihypertensive alpha-antagonist). (+)dobutamine also has about 7 times the beta-1 agonist effect as compared to (-)dobutamine. Both isomers are also partial agonists at the beta-2 receptor.

Confusing? Yes. In summary;

• Dobutamine is a potent (full) beta-1 agonist
• Dobutamine is a potent (partial) alpha agonist, which means it acts as an antagonist in situations where there is massive sympathetic overdrive (or co-administration of alpha agonist)
• Dobutamine is a weak (partial) beta-2 agonist, which means it acts as an antagonist in presence of  full beta-2 agonists like adrenaline or isoprenaline.